Ac-Leu-Leu-Nle-CHO

[ALLN, Calpain inhibitor I, Ac-LL-norleucinal]



BML-P120-0005	5 mg	72.00 USD

BML-P120-0025	25 mg	286.00 USD

Replaces Prod. #: ALX-260-037

Cell-permeable, peptide aldehyde inhibitor of calpain I (K_i=190nM), calpain II (K_i=150nM), cathepsin L (K_i=0.5nM) and other neutral cysteine proteases. Inhibits cell cycle progression at G1/S and metaphase/anaphase in CHO cells by inhibiting cyclin B degradation. Also stimulates HMG-CoA synthase transcription by inhibiting degradation of active SREBP-1 (sterol regulatory element-binding protein 1). Protects against neuronal damage caused by hypoxia and ischemia. Inhibits apoptosis in thymocytes and metamyelocytes.

Formula:	C₂₀H₃₇N₃O₄

MW:	383.54

Purity:	>95% (HPLC)

Appearance:	White powder.

Sequence:	N-Acetyl-Leu-Leu-Nle-CHO

CAS:	110044-82-1

Solubility:	Soluble in DMSO (25 mg/ml), 100% ethanol and methanol.

Shipping:	SHIPPED ON BLUE ICE

Long Term Storage:	-20°C

Background / Technical Information:	Please click here for the comprehensive product datasheet.

Product Literature References

Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex.: A. Vinitsky et al.; Biochemistry 31, 9421 (1992), Abstract;

Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.: M. Orlowski et al.; Biochemistry 32, 1563 (1993), Abstract;

In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal.: S.W. Sherwood et al.; Proc. Nat.l Acad. Sci. USA 90, 3353 (1993), Abstract;

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis.: X. Wang et al.; Cell 77, 53 (1994), Abstract;

Serine and cysteine proteinase inhibitors prevent nitric oxide production by activated macrophages by interfering with transcription of the inducible NO synthase gene.: J.M. Griscavage et al.; Biochem. Biophys. Res. Commun. 215, 721 (1995), Abstract;

Inhibitors of the proteasome pathway interfere with induction of nitric oxide synthase in macrophages by blocking activation of transcription factor NF-kappa B.: J.M. Griscavage et al.; Proc. Natl. Acad. Sci. USA 93, 3308 (1996), Abstract;

The protease inhibitor, N-acetyl-L-leucyl-L-leucyl-leucyl-L-norleucinal, decreases the pool of major histocompatibility complex class I-binding peptides and inhibits peptide trimming in the endoplasmic reticulum.: E.A. Hughes et al.; J. Exp. Med. 183, 1569 (1996), Abstract;

N-acetyl-leucinyl-leucinyl-norleucinal inhibits lipopolysaccharide-induced NF-kappaB activation and prevents TNF and IL-6 synthesis in vivo.: S.R. Schow & A. Joly; Cell. Immunol. 175, 199 (1997), Abstract;

Fas aggregation does not correlate with Fas-mediated apoptosis.: Y. Lee & E. Shacter; J. Immunol. 167, 82 (2001), Abstract;